Hope Rugo

Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development.

David Wholley, Anne Wallace, Michael Hogarth, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment.

Elizabeth A Rafferty, Kathy Schilling, F. Vicini, 2009, Journal of the American College of Surgeons.

A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor–Positive Breast Cancer

Mario Campone, H. Rugo, M. Campone, 2011, Clinical Cancer Research.

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

Thomas Bachelot, Florence Dalenc, Fabrice André, 2013, Clinical Cancer Research.

MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer

Ying Lu, Laura Esserman, Nola Hylton, 2001, Annals of Surgical Oncology.

Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)

Jame Abraham, Matthew P Goetz, H. Rugo, 2018, Breast Cancer Research and Treatment.

Tumor cell-adipocyte gap junctions activate lipolysis and are essential for breast tumorigenesis

Atul J. Butte, Daniel C. Liebler, Serghei Malkov, 2018 .

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

James Allison, Stephen Forman, Massimo Cristofanilli, 2015, Mayo Clinic proceedings.

Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

Andres Forero, James N. Ingle, Vered Stearns, 2013, Clinical Cancer Research.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

Anne Wallace, Emanuel F Petricoin, Rita Nanda, 2015, Clinical Cancer Research.